Korro Bio (NASDAQ:KRRO) Announces Earnings Results

Korro Bio (NASDAQ:KRRO) announced its quarterly earnings data on Tuesday. The company reported ($2.26) EPS for the quarter, topping analysts’ consensus estimates of ($2.33) by $0.07, Zacks reports. The business had revenue of $2.27 million for the quarter.

Korro Bio Price Performance

Shares of KRRO stock opened at $24.17 on Wednesday. The stock’s 50 day simple moving average is $30.70 and its 200 day simple moving average is $41.82. Korro Bio has a twelve month low of $18.50 and a twelve month high of $98.00.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KRRO. HC Wainwright reiterated a “buy” rating and set a $115.00 price target on shares of Korro Bio in a report on Friday, November 22nd. Oppenheimer began coverage on Korro Bio in a report on Friday, January 10th. They set an “outperform” rating and a $155.00 price target for the company. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $144.00.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).